ARCHIVES

FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225.

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

October 31, 2014

FDA Approves Treatment For Late-Stage Cervical Cancer

June 30, 2006

RFP, RFA Available

March 26, 1993

NCI Is On “Path To Stability,” Sondik Tells House Committee

April 7, 1995

Federal Standards Improve Mammogram Quality, GAO Finds

November 17, 1995

Fund Squeeze Results In Percentage reductions for Renewed Program Project, Center Core Grants

April 8, 1977